Direct Oral Anticoagulants Versus Warfarin and Enoxaparin in Ovarian Vein Thrombosis

Covut, Fahrettin; Kewan, Tariq; Pérez, Óscar; Thapa, Bicky; Babar, Arslan; Alomari, Mohammad; Haddad, Abdo; Daw, Hamed

doi:10.1097/mjt.0000000000001084

Cited by 14 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are 3 published case reports evaluating the use of rivaroxaban 86,87 or apixaban 88 11 VKAs and 15 enoxaparin. 89 During follow-up, recanalization was achieved in 70% of women in the DOAC group versus 55% in the VKA group versus 93% in the LMWH group. The 1-year cumulative incidence of clinically significant bleeding events was 10% versus 18% versus 25% in the three groups, respectively.…”

Section: Evidence Regarding Doacsmentioning

confidence: 93%

“…There are 3 published case reports evaluating the use of rivaroxaban 86,87 or apixaban 88 in young women with OVT, with promising results. Finally, Covut et al 89 retrospectively assessed the treatment of 36 women with OVT evaluated at the Cleveland Clinic (United States) in the years 2012‐2018. They found that 10 women received DOACs (rivaroxaban or apixaban), 11 VKAs and 15 enoxaparin 89 .…”

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

“…Finally, Covut et al 89 retrospectively assessed the treatment of 36 women with OVT evaluated at the Cleveland Clinic (United States) in the years 2012‐2018. They found that 10 women received DOACs (rivaroxaban or apixaban), 11 VKAs and 15 enoxaparin 89 . During follow‐up, recanalization was achieved in 70% of women in the DOAC group versus 55% in the VKA group versus 93% in the LMWH group.…”

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

“…The 1-year cumulative incidence of clinically significant bleeding events was 10% versus 18% versus 25% in the three groups, respectively. 89…”

Section: Evidence Regarding Doacsmentioning

confidence: 99%

See 3 more Smart Citations

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer drug interactions, faster onset of action, shorter half‐life, and lower risk of major and intracranial bleeding. Although the evidence on the use of DOACs in patients with unusual‐site venous thromboembolism (VTE) is limited to a few, small randomized controlled trials, these drugs are increasingly used in clinical practice, and several observational cohort studies have been published recently. This narrative review will describe the latest evidence for the use of the DOACs in patients with thrombosis in atypical locations (splanchnic, cerebral, upper extremity, ovarian, and renal vein thrombosis) and will provide some practical advice for their use in patients with unusual‐site VTE.

show abstract

Section: Evidence Regarding Doacsmentioning

confidence: 93%

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

“…The 1-year cumulative incidence of clinically significant bleeding events was 10% versus 18% versus 25% in the three groups, respectively. 89…”

Section: Evidence Regarding Doacsmentioning

confidence: 99%

See 2 more Smart Citations

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…5 In the study by Covut et al, the 1-year cumulative incidence of major bleeding was 0% in 10 women with OVT receiving DOACs, 13% in 11 women receiving VKA, and 9% in 15 women receiving LMWH. 66 However, the small sample size and the observational design limit the generalizability of these results (e.g., possible unbalanced baseline characteristics).…”

Section: Hämostaseologiementioning

confidence: 98%

Ovarian Vein Thrombosis: A Narrative Review

Riva

Calleja‐Agius

2020

Hamostaseologie.

View full text Add to dashboard Cite

Ovarian vein thrombosis (OVT) is a rare type of venous thromboembolism. The most common risk factors for OVT include pregnancy, oral contraceptives, malignancies, recent surgery, and pelvic infections; however, in 4 to 16% of cases, it can be classified as idiopathic. Most of the available information regards pregnancy-related OVT, which has been reported to complicate 0.01 to 0.18% of pregnancies and to peak around 2 to 6 days after delivery or miscarriage/abortion. The right ovarian vein is more frequently involved (70–80% of cases). Clinical features of OVT include abdominal pain and tenderness, fever, and gastrointestinal symptoms. The most typical finding is the presence of a palpable abdominal mass, although reported in only 46% of cases. OVT can be the cause of puerperal fever in approximately a third of women. Ultrasound Doppler is the first-line imaging, because of its safety, low cost, and wide availability. However, the ovarian veins are difficult to visualize in the presence of bowel meteorism or obesity. Thus, computed tomography or magnetic resonance imaging is often required to confirm the presence and extension of the thrombosis. In oncological patients, OVT is often an incidental finding at abdominal imaging. Mortality related to OVT is nowadays low due to the combination treatment of parenteral broad-spectrum antibiotics (until at least 48 hours after fever resolution) and anticoagulation (low-molecular-weight heparin, vitamin K antagonists, or direct oral anticoagulants). Anticoagulant treatment duration of 3 to 6 months has been recommended for postpartum OVT, while no anticoagulation has been suggested for incidentally detected cancer-associated OVT.

show abstract